Onepharm Research and Development GmbH

Onepharm Research and Development GmbH (OnePharm) is a dental pharmaceutical company, engaged in chemical, clinical and formulation development of small molecule drugs for the treatment of viral diseases. The company has developed a strong network with academic research centers to strengthen its scientific knowledge base and new product development. Currently, OnePharm is developing therapeutics for viral respiratory tract diseases such as the common cold, influenza, bird flu, and SARS. Its product pipeline includes OPM 1001, a small molecule substance with antiviral activity against human rhino virus; and OPM 3001, a product isolated from licorice roots that works against SARS Covers in-vitro in combination with Ribavirin. Further, the company along with the European Molecular Biology Laboratory (EMBL) founded Savira Pharmaceuticals for the development of novel anti-influenza drugs and medicinal chemistry programs. In addition, OnePharm has developed OPM-3023 as its most advanced pipeline product for inhibition of inflammation-induced periodontal bone loss, rheumatoid arthritis and inflammatory bowl disease. The company is headquartered in Vienna, Austria.

Street: 
Veterinarplatz 1
City: 
Vienna
Postcode: 
1210
Federal State : 
Austria
WebSite: 
www.onepharm.com
Fax: 
43-1-250775999

Company Index Score

Current Index Score Historical Index Score
  • Onepharm Research and Development GmbH currently scores 50 % in the index.
  • Onepharm Research and Development GmbH is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Onepharm Research and Development GmbH is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets